MRIdian Clinical and Research Experience Featured in Nearly 40 Abstracts at ESTRO 2022, the Leading European Radiation Oncology Meeting

CLEVELAND, May 6, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO), with nearly 40 presentations and posters highlighting MRIdian clinical and research experience. This year's ESTRO meeting will be held May 6-10, 2022 online and in-person in Copenhagen, Denmark.